Immunotherapy in Multiple Myeloma: Boom or Bust? Investigating Oligoclonal Banding and Survival in Multiple Myeloma Patients Receiving Anti CD3-CD28 Co-Stimulated and Engineered Autologous T cells after Autologous Stem Cell Transplant.

In some patients with multiple myeloma (MM), the original M protein disappears and one or multiple smaller immunoglobulins, called oligoclonal bands (OCB), emerge following autologous stem cell transplant (ASCT). OCB are associated with improved disease-free survival (DFS) and may be associated with early immune system recovery. Patients in phase I/II clinical trials at the University of Maryland Greenebaum Cancer Center who received anti CD3-CD28 co-stimulated and engineered autologous T cells shortly after ASCT had early, rapid, and robust T cell recovery.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research